⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
AMBUJACEM - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.5
| Stock Code | AMBUJACEM | Market Cap | 1,26,224 Cr. | Current Price | 511 ₹ | High / Low | 625 ₹ |
| Stock P/E | 35.2 | Book Value | 206 ₹ | Dividend Yield | 0.40 % | ROCE | 8.80 % |
| ROE | 8.77 % | Face Value | 2.00 ₹ | DMA 50 | 544 ₹ | DMA 200 | 557 ₹ |
| Chg in FII Hold | -0.11 % | Chg in DII Hold | 0.23 % | PAT Qtr | 227 Cr. | PAT Prev Qtr | 1,571 Cr. |
| RSI | 32.0 | MACD | -8.85 | Volume | 22,47,679 | Avg Vol 1Wk | 36,51,305 |
| Low price | 455 ₹ | High price | 625 ₹ | PEG Ratio | 1.70 | Debt to equity | 0.02 |
| 52w Index | 32.7 % | Qtr Profit Var | -87.1 % | EPS | 13.7 ₹ | Industry PE | 30.0 |
📈 Technical Analysis
- Chart Patterns: Price (511 ₹) is below both 50 DMA (544 ₹) and 200 DMA (557 ₹), showing weakness.
- Moving Averages: Downward bias as stock trades under short- and long-term averages.
- RSI: At 32.0, oversold territory, potential rebound signal.
- MACD: Negative (-8.85), bearish crossover persists.
- Bollinger Bands: Price near lower band, support seen around 500–510 ₹.
- Volume Trends: Current volume (22.47L) is below 1-week average (36.51L), showing weak participation.
🎯 Momentum & Trade Zones
- Support Levels: 500–510 ₹ (near Bollinger lower band), 455 ₹ (recent low).
- Resistance Levels: 544 ₹ (50 DMA), 557 ₹ (200 DMA), 600 ₹ (psychological barrier).
- Entry Zone: 500–515 ₹ (accumulation near support).
- Exit Zone: 540–560 ₹ (profit booking near resistance).
- Trend: Reversing from oversold conditions; short-term bounce possible if RSI recovery sustains.
✅ Positive
- Debt-to-equity ratio at 0.02, virtually debt-free.
- DII holdings increased (+0.23%), showing domestic institutional confidence.
- PEG ratio (1.70) indicates fair valuation relative to growth.
- 52-week index return of 32.7% highlights long-term resilience.
⚠️ Limitation
- Stock trading below both 50 DMA and 200 DMA, reflecting technical weakness.
- High P/E (35.2) compared to industry average (30.0), suggesting overvaluation.
- ROCE (8.80%) and ROE (8.77%) reflect modest efficiency.
- Dividend yield at 0.40% provides limited income support.
📉 Company Negative News
- Quarterly PAT dropped sharply (227 Cr. vs 1,571 Cr.), profit variance at -87.1%.
- FII holdings decreased (-0.11%), showing reduced foreign investor confidence.
📊 Company Positive News
- DII holdings increased (+0.23%), reflecting domestic support.
- EPS at 13.7 ₹ provides valuation strength despite weak profitability.
🏭 Industry
- Industry P/E at 30.0, lower than company’s 35.2, suggesting sector peers may be more attractively priced.
- Cement sector demand remains steady, driven by infrastructure and housing growth.
📝 Conclusion
- AMBUJACEM is oversold (RSI 32.0) and may see a short-term rebound.
- Optimal entry near 500–515 ₹ with exit around 540–560 ₹.
- Strong long-term resilience, but weak quarterly earnings and modest efficiency limit upside.
- Medium-term investors should wait for breakout above 544–557 ₹ to confirm reversal trend.